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ARTICLE
Extensive rewiring of the EGFR network in
colorectal cancer cells expressing transforming
levels of KRASG13D
Susan A. Kennedy et al.#
Protein-protein-interaction networks (PPINs) organize fundamental biological processes, but
how oncogenic mutations impact these interactions and their functions at a network-level
scale is poorly understood. Here, we analyze how a common oncogenic KRAS mutation
(KRASG13D) affects PPIN structure and function of the Epidermal Growth Factor Receptor
(EGFR) network in colorectal cancer (CRC) cells. Mapping >6000 PPIs shows that this
network is extensively rewired in cells expressing transforming levels of KRASG13D
(mtKRAS). The factors driving PPIN rewiring are multifactorial including changes in protein
expression and phosphorylation. Mathematical modelling also suggests that the binding
dynamics of low and high afﬁnity KRAS interactors contribute to rewiring. PPIN rewiring
substantially alters the composition of protein complexes, signal ﬂow, transcriptional reg-
ulation, and cellular phenotype. These changes are validated by targeted and global experi-
mental analysis. Importantly, genetic alterations in the most extensively rewired PPIN nodes
occur frequently in CRC and are prognostic of poor patient outcomes.
https://doi.org/10.1038/s41467-019-14224-9 OPEN
#A full list of authors and their afﬁliations appears at the end of the paper.
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PPINs are a major principle of biological organization. Sev-eral large-scale studies have demonstrated their importancein organizing fundamental cellular processes1–4. Increasing
evidence suggests that PPINs are altered in human disease and
that such changes contribute to pathogenesis3,5,6. However, we
lack a clear comprehension of how such changes occur and how
they affect PPIN function. This particularly applies to oncogenic
mutations, where we rarely understand how system wide effects
are generated. For instance, oncogenic RAS mutations, which
activate the ability of RAS proteins to engage downstream
effectors, occur in ~30% of all human cancers7. RAS mutated
cancers are resistant to most targeted therapies, and inhibiting
downstream effectors has proven ineffective, likely because of
complex feedback structures in the downstream pathways and the
large number of effector pathways8. These impediments highlight
the need for a systems level understanding of the RAS signaling
network and the changes associated with RAS transformation8.
The KRASG13D mutation (mtKRASG13D) investigated here is the
second most frequent RAS mutation in CRC7, and is associated
with aggressive behavior and poor clinical outcomes9.
We use quantitative mass spectrometry (qMS) to map KRAS
regulated PPINs in two closely related CRC cell lines that express
either transforming or non-transforming levels of mtKRASG13D.
Focusing on the epidermal growth factor receptor (EGFR) signaling
network, where KRAS plays a key role in CRC10, we analyze 1710
immunoprecipitates and map >6000 PPIs involved in EGFR sig-
naling (Fig. 1). To analyze this dataset we develop an analysis
pipeline for the quantitative comparison of PPIN data between
different cell lines. Finding that the expression of transforming
levels of mtKRAS correlates with substantial rewiring of the EGFR
PPIN, we analyze the functional consequences of this rewiring on
protein complex assemblies, information ﬂow, and biological
responses including the prognosis of CRC patients. To facilitate the
utilization of this extensive data for further research we develop
PRIMESDB.eu (https://primesdb.eu/), an integrated database and
analysis platform for exploring the PPINs described here.
Results
Mapping the EGFR PPIN in mtKRAS Cells. We mapped the
effects of mtKRAS on PPINs downstream of the EGFR in HCT116
cells, which have been widely used to study mtKRAS functions in
CRC. HCT116 harbor an oncogenic KRASG13D allele, which was
targeted for disruption by homologous recombination to generate
the non-tumorigenic HKE3 cells11. A thorough genetic, biochem-
ical and biological characterization described in a previous pub-
lication12 and Supplementary Fig. 1 conﬁrmed that HCT116 and
HKE3 are closely related cell lines. Compared to HCT116 cells,
HKE3 had a non-transformed phenotype, as reﬂected by EGFR
inhibitor sensitivity and reduced migration, proliferation, colony
forming ability, and anchorage independent growth (Supplemen-
tary Fig. 1). Interestingly, despite this non-transformed phenotype
HKE3 cells retain a genetically stable low-level expression of
mtKRASG13D, likely due to a duplication of the mutant
mtKRASG13D allele in HCT116 and knockout of only one copy in
the HKE3 cells (Supplementary Fig. 1A). Recent ﬁndings indicate
that oncogenic KRAS mutations occur in normal tissues and that
KRAS activity needs to exceed a threshold to drive cancer pro-
gression and metastasis13–16. Thus, this cell line pair offers the
opportunity to compare the EGFR PPIN in cells expressing
a transforming vs. a non-transforming dosage of mtKRAS.
Furthermore, HCT116 are not addicted to mtKRAS for survival,
minimizing selection pressure to acquire compensatory mutations
when mtKRAS dosage is reduced17.
To attain a representative coverage of the EGFR PPIN we
selected 95 bait proteins (Supplementary Data 1) based on a
highly curated EGFR signaling network map18 and a literature
survey of the EGFR pathways involved in CRC pathogenesis and
progression. The baits cover the main functions of EGFR
signaling including key kinases, phosphatases, scaffold and
adapter proteins in the network. The baits were expressed as
FLAG-tagged proteins carefully titrating transfection to achieve a
similar expression level in both cell lines. Baits were immuno-
precipitated and associated prey proteins were identiﬁed by
high-resolution Orbitrap qMS. To ensure high data quality, we
analyzed 95 bait and empty vector control immunoprecipitates
(IPs) from both forward and reverse SILAC labeled cells using
three biological and two technical replicates per bait resulting in
1710 samples and 1140 qMS analyses (Fig. 1). As common
analysis methods for AP-MS data are ill suited for quantitatively
comparing PPI data from different cell lines and from a biased
bait selection, we used HiQuant19, which we speciﬁcally
developed analyse MS data from complex experiments such as
ours. The pipeline includes rigorous steps for data quality control,
normalization, statistical analysis, and network construction. This
workﬂow includes a stringent two-step procedure to exclude false
positive interactors (Supplementary Methods, section 12). The
EGFR PPINs in the HCT116 and HKE3 cells, termed EGFR-
NetmtKRAS-Hi and EGFRNetmtKRAS-Lo, respectively, were recon-
structed from high-conﬁdence bait–prey interactions.
EGFR PPIN network architecture. EGFRNetmtKRAS-Hi and
EGFRNetmtKRAS-Lo consist of 3162 and 2788 bait-prey interac-
tions, respectively (Supplementary Fig. 2A–E, Supplementary
Data 2). This network size is within the expected distribution of
known PPINs (Supplementary Fig. 3A). 93 of the 95 baits had a
least one prey detected in both cell lines. More than 70% of preys
in EGFRNetmtKRAS-Lo were also nodes in EGFRNetmtKRAS-Hi,
indicating that most nodes are true components of the EGFR
PPIN, since they were independently detected in both cell lines.
Both EGFRNets are small-world, single-component networks
(i.e., all nodes are reachable from one another) with similar scale-
free topologies and comparable other network properties such as
average path length, node degree, betweenness centrality (bc), and
clustering coefﬁcients (Supplementary Fig. 2F–I). For example,
many of the major hubs (highly connected nodes) in EGFR-
NetmtKRAS-Hi are also hubs in EGFRNetmtKRAS-Lo including
GRB2, RAB5A, RAF1, and SH2D3C. While GRB2 is a well-
known hub coordinating different aspects of EGFR signaling20,
some of the other high bc nodes are thought to have specialized
functions. Our data suggest that these proteins are involved in a
far greater degree of crosstalk with other cellular processes than
previously assumed.
A comparison with currently known PPIs shows that >80% of
interactions discovered in our study are new, attesting to the value
of focused PPIN mapping studies complementing genome-wide
efforts and suggesting that many PPIs may be highly dependent on
the cellular context. Such a high proportion of novel interactions is
consistent with other large-scale, AP-MS based, interactome
mapping efforts1,2,4,21,22. Testing 17 arbitrarily chosen interactions
using conventional co-immunoprecipitation/Western blot experi-
ments showed that the PPI data were highly reproducible by a
different method (Supplementary Fig. 3B, C).
As AP-MS may underrepresent interactors of integral mem-
brane proteins23, we used MYTH, a membrane yeast two-hybrid
assay24, to identify binary protein interactors of the human EGFR
family, ERBB1–4 (Supplementary Methods, section 30). This
interactome map comprised 405 interactions (Supplementary
Fig. 4 and Supplementary Data 3) including 181 new interactions.
All bait–prey interactions detected in theEGFRNets can be
explored in the Supplementary Data and at http://primesdb.eu/.
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Fig. 1 Experimental and data analysis workﬂow for the comparative mapping of PPIs in the EGFR network. Baits were chosen based on the core EGFR
network described by Kiel et al.18 and additional manually curated literature information. Flag-tagged expression vectors were constructed using the
Gateway cloning system and transfected into HCT116 (mtKRASHi) and HKE3 (mtKRASLo) cells. Careful titration of the transfected plasmids ensured similar
protein expression in both cell lines grown in SILAC media as monitored by Western blotting. For MS experiments similar amounts of baits were expressed
in SILAC labeled HCT116 and HKE3 cells and immunoprecipitated (IP) with anti-Flag antibodies. To assure robust quantitation the SILAC label was
swapped, i.e. each bait was isolated from HCT116 and HKE3 cells grown in heavy or light medium, respectively. After trypsin digestion peptides were
identiﬁed and quantiﬁed by orbitrap mass spectrometry. Raw data were analysed using MaxQuant59 and further processed using HiQuant19 implementing
a stringent pipeline to retain only true interactors. Based on these data two quantitative protein–protein interaction networks, termed EGFRNetmtKRAS-Hi
and EGFRNetmtKRAS-Lo, were reconstructed and are shown in a combined differential network representation. EV Ctrl, empty vector control transfection.
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mtKRASHi induces extensive PPIN rewiring. To identify
interactions that were signiﬁcantly rewired in mtKRASHi cells,
i.e., interactions that were gained/lost in one EGFRNet or present
in both but with signiﬁcantly altered prey abundance, we statis-
tically compared prey abundance between each bait-prey complex
in the EGFRNets. Of the 4420 bait–prey interactions detected in
at least one EGFRnet (Supplementary Data 4), 1368 were sig-
niﬁcantly rewired i.e., prey abundance was signiﬁcantly different
between the two PPINs at P ≤ 0.05, signiﬁcance A ≤ 0.05 (Sup-
plementary Data 5). Six hundred and thirty four of the rewired
interactions were edges only in EGFRNetmtKRAS-Hi, and 406 were
edges only in EGFRNetmtKRAS-Lo indicating that most rewiring is
due to interaction gains or losses (Fig. 2). The 328 remaining
rewired interactions were present in both networks but with
signiﬁcantly different prey abundances (P ≤ 0.05, signiﬁcance A ≤
0.05). These data suggest that the oncogenic mtKRAS activity in
mtKRASHi cells initiates a ripple effect throughout the network
substantially altering network topology far beyond direct KRAS
interactors.
Potential drivers of PPIN rewiring. To investigate which
molecular mechanisms could drive PPIN rewiring, we ﬁrst ana-
lyzed whether genetic mutations other than KRASG13D played a
role, since genetic variation has previously been associated with
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PPIN rewiring25. Using whole genome sequencing we identiﬁed
genetic alterations, including copy number variations (CNVs),
insertions/deletions (InDels), synonymous and nonsynonymous
single-nucleotide-variants (SNVs) between the two cell lines
(Supplementary Data 6–8; Supplementary Fig. 5A). Using
the Genome Analysis Toolkit26 27 genes were predicted to be
impacted by structural variants, but no gene was a node in the
EGFRNets. Considering CNVs, ﬁve genes were EGFRNet nodes,
but only one gene product, PPP3CA, was rewired. Of the 170,135
SNVs and small InDels found different between mtKRASHi and
mtKRASLo cells 1091 were variants of predicted high/medium
impact27 (Supplementary Data 6). Of these, 70 were nodes in the
EGFR PPI network and 36 were rewired. Considering that
EGFRnets contain 4420 nodes, of which 1360 have rewired
interactions, SNVs affect 1.6% of nodes and 2.6% of rewired
interactions. These data suggest that structural variants, SNVs
and CNV-driven changes in gene/protein expression have limited
impact on EGFRNet rewiring. Nonetheless, we cannot rule out
that these or other genetic differences inﬂuence some PPIs by
affecting gene promoter usage, mRNA editing, or codon usage.
We also considered that rewired prey could simply represent
lowly or highly expressed nodes. However, we found no bias in
the gene expression distribution of rewired nodes compared to
unchanged nodes (Supplementary Fig. 5B) suggesting that genetic
changes that alter gene/protein expression, e.g., CNVs, do not
make major contributions to PPIN rewiring.
To further explore this, we directly tested whether changes in
protein expression between the two cell lines are linked to the
observed EGFRNet rewiring. We proﬁled protein abundances in
the mtKRASHi and mtKRASLo cell lines using qMS (Supplemen-
tary Data 9). 404 of the 4685 proteins quantiﬁed showed a
signiﬁcant difference in abundance (P ≤ 0.05). Pathway analysis
revealed that proteins more abundant in mtKRASHi were
enriched for roles in the cell cycle, consistent with the increased
proliferation rate of these cells (Supplementary Fig. 1E). By
contrast, proteins more abundant in mtKRASLo cells were
enriched for roles in oxidative phosphorylation, lipid metabolism,
and the lysosome. The decreased expression of proteins involved
in oxidative phosphorylation in mtKRASHi cells is consistent with
a metabolic switch from oxidative phosphorylation to glycolysis, a
hallmark of cancer cells known as the Warburg effect28. A
strong relationship between KRASG12D dosage and increased
glycolysis was recently reported29. Similarly, lipid metabolism
reprogramming is also a hallmark of cancer cells, including CRC
cells30.
We found a weak (r2= 0.18) but signiﬁcant correlation
(P < 0.001) between fold-change in abundance in the AP-MS
protein complexes and fold-change in protein expression between
the cell lines (Supplementary Fig. 5C). One hundred and fourteen
differentially expressed (DE) proteins were nodes in the
EGFRNets (Fig. 3a, Supplementary Fig 5D, E), two of them
corresponding to baits (RPS6KA1 and SH3KBP1, Δ= 1.7-fold).
This was not more than statistically expected (P= 0.054)
indicating that the EGFR network was not especially enriched
for DE proteins. However, 74 of the 114 DE proteins represented
rewired nodes, which was statistically signiﬁcant (P= 4.21E−5),
conﬁrming an association between differential node abundance
and network rewiring. Interestingly, some bait-prey complexes
were particularly enriched for DE proteins (Supplementary
Fig. 5F, G). For example, of 71 rewired preys in the SH2D3C
complex, 16 (22%) were also DE. Overall, these data suggest that
differences in protein expression between mtKRASHi and
mtKRASLo cells may underlie some of the rewired interactions.
However, this association was lost when considering proteins at
DE >2-fold. Furthermore, as ~90% of rewired nodes were not
identiﬁed as DE proteins, differences in protein expression
alone cannot explain the wide-spread network rewiring. We have
not investigated the reverse possibility that PPIs may affect
protein stability31,32.
To assess other potential drivers of PPIN rewiring, we
examined protein phosphorylation, which can generate docking
sites and affect binding afﬁnities between proteins, thereby
inﬂuencing protein complex formation. qMS-based phosphopro-
teome analysis of mtKRASHi and mtKRASLo cells identiﬁed 384
differentially phosphorylated proteins (Supplementary Data 10).
Two hundred and seventy one proteins were preferentially
phosphorylated in mtKRASHi cells and were enriched for roles in
cell cycle and apoptosis related pathways, while the 121 proteins
preferentially phosphorylated in mtKRASLo cells were weakly
enriched for cytokine signaling and related processes (Supple-
mentary Data 10). Eighty nine differentially phosphorylated (DP)
proteins were nodes in the EGFRNets (Fig. 3b). Compared to the
number of network nodes that were also represented in the
phosphoproteomics screen, this was not more than statistically
expected (P= 0.06) indicating that the EGFRNets were not
enriched for DP proteins. However, 56 of the 89 DP proteins
(63%) mapping to EGFRNets were also signiﬁcantly rewired
nodes (P < 0.01). Interestingly, this association was even stronger
when considering interactions that were enhanced (or only
found) in EGFRNetmtKRAS-Hi. Rewiring of these interactions was
signiﬁcantly correlated with higher phosphorylation in the
mtKRASHi cells (P < 0.001). These results suggest that differential
phosphorylation could contribute to PPIN rewiring, especially
when mtKRAS signaling is high (Supplementary Fig. 5F, G).
However, as with differentially expressed proteins, the majority of
rewired nodes were not associated with differential phosphoryla-
tion. This suggests that the observed network rewiring is an
emergent property of the changed cellular state in cells expressing
transforming levels of mtKRAS and is not readily predicted by
changes in any single factor such as protein expression or
phosphorylation.
PPIN rewiring modiﬁes protein complexes and their functions.
Pathway analysis of all 735 prey proteins involved in rewired
interactions revealed a statistically signiﬁcant enrichment for
roles in processes including RNA splicing, mitochondrial trans-
lational, protein folding by the chaperonin-containing-TCP1
(CCT) complex and cell migration (Fig. 3c, Supplementary
Data 11). Interestingly, CRISPR and shRNA-based screens of
HCT116 cells and isogenic wild-type KRAS derivatives found that
synthetic lethal KRASG13D genes had roles in mRNA splicing and
mitochondrial translation, and that these processes were required
for KRASG13D oncogenicity33. Proteins encoded by synthetic
lethal genes identiﬁed in this CRISPR screen were signiﬁcantly
enriched (9 of 55; P < 0.01) for rewired PPIs in our network. The
shRNA screen in this study identiﬁed several CTT components as
synthetic lethal genes. In our study, several baits co-precipitated
the entire CCT complex in both mtKRASHi and mtKRASLo cells
(Supplementary Data 4), with interactions between CCT and the
baits BMX, LCK, and PTK6, being signiﬁcantly rewired (Sup-
plementary Data 5).
Similar correlations were observed when assessing how PPIN
rewiring affected the composition of known protein complexes
described in CORUM, a curated database of experimentally
determined mammalian protein complexes34. We detected 42
and 40 CORUM complexes where at least 70% of their
component proteins were nodes in EGFRNetmtKRAS-Hi and
EGFRNetmtKRAS-Lo, respectively (Supplementary Fig. 6, Supple-
mentary Data 12). Several of these CORUM complexes are
involved in processes mediated by EGFR signaling including actin
cytoskeleton organization, RAF, and NFκB signaling35,36.
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However, other complexes participate in functions not usually
associated with EGFR signaling, e.g. chromatin modiﬁcation,
regulation of protein folding, mRNA splicing and protein
translation. This analysis suggests that PPIs organize different
aspects of EGFR signaling including roles that have not been
characterized yet. Most CORUM complexes were present in both
networks, although some were extensively rewired. CORUM
complexes, where >60% of constituent proteins were rewired
preys, included complexes involved in mRNA transcription,
splicing and protein folding (Supplementary Fig. 6) suggesting
that such house-keeping functions support mtKRAS transforma-
tion. Furthermore, complex formation can stabilize proteins31
and may contribute to the differential protein abundance between
mtKRASHi and mtKRASLo cells.
Interestingly, rewired interactions were non-randomly distrib-
uted across the bait-prey complexes (Supplementary Fig. 7).
Many bait-prey complexes, including AKT1, FGR, HDAC1,
LYN, MAPK3 (ERK1), RIPK1, and TNK1 complexes, had no
signiﬁcantly rewired interactions, while others, such as MAP2K1
(MEK1), RAC1, and SH2D3C, were substantially rewired
(Supplementary Data 5). In some cases, rewiring predominantly
involved the gain of new bait–prey interactions in mtKRASHi
cells. For example, all 25 rewired bait–prey interactions in the
BAD complex were only detected or signiﬁcantly more abundant
in the EGFRNetmtKRAS-Hi (Fig. 4a). BAD is a proapoptotic
protein37, which contributes to the higher apoptosis rate of
mtKRASHi vs. mtKRASLo cells, as shown by siRNA knockdown
experiments (Fig. 4b). Interestingly, the BAD interactions
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Fig. 3 Potential drivers of the EGFR PPI network rewiring. a The number of rewired prey proteins for each bait-prey AP-MS complex that were assessed
for differential protein expression between the two cell lines. Rewired prey proteins that were signiﬁcantly more abundant in the mtKRASHi cells are shown
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enhanced in EGFRNetmtKRAS-Hi included a higher abundance of
protein phosphatase 2A (PP2A) family members (Supplementary
Data 5), which correlated with a lower phosphorylation of BAD
on S112 and S155 in HCT116 (Fig. 4c). These sites inactivate
BAD’s pro-apoptotic function and can be phosphorylated by
cAMP dependent protein kinase (PRKA)37, which interacted with
BAD in both cell lines. Inhibition of PRKA reduced S112 and
S155 phosphorylation in mtKRASLo cells, while PRKA inhibition
increased BAD phosphorylation in mtKRASHi, especially on S112
(Fig. 4c). This differential action of PRKA is likely due to its
ability to activate PP2A by phosphorylating the B56δ subunit
(PPP2R5)38, which is mainly bound to BAD in mtKRASHi cells.
Consequently, PRKA inhibition preferentially enhanced apopto-
sis in mtKRASLo cells (Fig. 4d). These results suggest that PPI
rewiring can profoundly subvert the biological effects of PRKA
signaling, in this case converting a survival signal into a pro-
apoptotic signal (Fig. 4e).
Another substantially rewired node was PTK6 (Supplementary
Fig. 8). PTK6 is a poorly characterized tyrosine kinase, which is
ampliﬁed or overexpressed in 16% of CRC patients. PTK6 can
stimulate CRC cell survival and oncogenic signaling in a kinase
dependent manner, but suppresses epithelial-to-mesenchymal
transition in a kinase independent fashion39. PTK6 rewiring
mostly decreased interactions with the CCT chaperonin complex
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in mtKRASHi cells, whereas the interaction with metastasis
associated 1 family member 2 (MTA2) was increased (Supple-
mentary Fig. 8A). Given the key role that MTA2 plays in cell
motility and metastasis40, we examined whether PTK6 con-
tributed to the differential cell migration observed between
mtKRASHi and mtKRASLo cells (Supplementary Fig. 1F).
mtKRASHi and mtKRASLo expressed similar amounts of
endogenous PTK6 (Supplementary Fig. 8B). Overexpressing
PTK6 accelerated migration in HCT116 cells but inhibited it in
HKE3 cells (Supplementary Fig. 8C). Increased migration was
dependent on PTK6 kinase activity, as a kinase dead PTK6
mutant slowed migration (Supplementary Fig. 8D). Knocking
down endogenous PTK6 decreased migration speciﬁcally in
mtKRASHi but not in mtKRASLo cells (Supplementary Fig. 8E).
Taken together, these results suggest that PTK6 preferentially
enhances migration in cells with high KRAS activity.
Network rewiring alters information ﬂow through EGFRNets.
The extensive changes in network wiring and protein complex
composition suggested that PPIN rewiring may alter signal pro-
cessing in the EGFR network. First, we explored how different
concentrations of active KRAS affects the formation of KRAS
complexes with known effector proteins. Activated RAS proteins
signal by binding a range of effectors through a single, shared
binding domain7 leading to competition between effectors. To
analyze the formation of speciﬁc KRAS-effector complexes we
constructed an equilibrium binding model of proteins competing
for a single target (see Methods section). This model classiﬁes
KRAS effectors into low and high afﬁnity binders, whose binding
dissociation constants (Kd’s) are greater or smaller, respectively,
than the abundance of active KRAS. It shows that for low-afﬁnity
effectors the corresponding KRAS complex concentrations are
proportional to the effector concentration divided by the Kd,
whereas for high-afﬁnity interactors the resulting KRAS com-
plexes concentrations are determined by the abundance of active
KRAS and effectors alone. Thus, changes in mtKRAS con-
centration can profoundly rearrange the composition of KRAS-
effector complexes, which rather than changing the strengths of
downstream pathway activation shifts signaling from high to low
afﬁnity effectors as mtKRAS dosage increases (Fig. 5a). As mea-
sured by quantitative Western blotting, the mtKRAS concentra-
tions in mtKRASLo and mtKRASHi cells are ~150 nM and ~400
nM, respectively, indicating that high afﬁnity RAS effector com-
plexes prevail in mtKRASLo cells, while low afﬁnity effectors
dominate signaling in mtKRASHi cells. Speciﬁcally, the model
predicted that fold-changes in KRAS-bound fractions are higher
for low-afﬁnity than for high-afﬁnity effectors. Ranking effectors
by the fold-changes in KRAS-bound fractions allowed us to
estimate their relative contribution to downstream signaling.
Applying this analysis to baits that participate in bona-ﬁde KRAS
effector pathways (RAF/MAPK, RAL, PI3K, TIAM, AFDN, PLCε,
and RIN1), we calculated the sensitivity of a node responding to
different mtKRAS doses by summing the log fold-changes of
interactions (normalized by the number of pathway nodes mea-
sured) in each bait-prey AP-MS complex. These experimentally
deduced sensitivity ranks of KRAS-effector complexes correlated
with the model-predicted ranks (Supplementary Data 13). These
results suggest that the threefold difference in mtKRAS activity
induces the formation of very different KRAS-effector complexes
that initiate network rewiring by engaging different signaling
pathways (rather than stronger activate the same set) that pro-
pagate changes further downstream.
Given these extensive changes in network wiring and protein
complex composition we hypothesized that PPIN rewiring would
also alter signal processing, leading to differential activation of
downstream transcriptional programs. In order to investigate this
hypothesis in an unbiased way not limited to known KRAS
effector pathways, we employed a computational modeling based
approach called information ﬂow (IF) analysis41,42. This method
simulates IF in a network through discrete-time random walks
from a source node, i.e., EGFR, to downstream sinks, i.e.,
transcription factors (TFs). To model the impact of PPIN
rewiring, we simulated IF independently in the EGFRNetmtK-
RAS-Hi and EGFRNetmtKRAS-Lo networks and calculated an IF
score (IFS) for each node in the two networks that reﬂects the
volume of signals ﬂowing through a node. Nodes with high IFS in
both networks included known key transducers of EGFR
signaling, e.g., GRB243, indicating that major hubs are used
regardless of mtKRAS dosage. However, 119 nodes had a >2-fold
difference in IFS in EGFRNetmtKRAS-Hi vs. EGFRNetmtKRAS-Lo
(Fig. 5b and Supplementary Data 14), indicating potentially
critical differences in signal processing. Interestingly, many of the
highest scoring nodes that received more information ﬂow
in the EGFRNetmtKRAS-Hi network were proteins involved in
protein folding including heat shock protein (HSP) 70 family
members (HSPA1A and HSPA8), and HSP90 family members
(HSP90AA1, HSP90AB1, and HSP90AB3P). HSP70 and HSP90
expression is upregulated in many cancers including CRC44, and
high HSP70 expression is associated with poor clinical outcomes
in CRC45. Furthermore, HSP90 inhibitors are in clinical trials for
several cancers including CRC46. Another node with higher IFS
in EGFRNetmtKRAS-Hi was SRC, which is a major promoter of
CRC proliferation, metastasis, drug resistance, and is over-
expressed in ~80% of CRCs47. These data suggest that network
nodes with increased IF in mtKRASHi cells contribute to the
molecular pathogenesis of CRC and may represent potential
drug targets.
Next, we assessed whether PPIN rewiring alters IF to
transcription factors (TFs) in the EGFRNets (Fig. 5c). FOXO1
and MYC were predicted to receive higher IF in EGFRNetmtKRAS-
Hi. Assessing gene expression in both cell lines by RNAseq prior
to and following EGFR activation by TGFα, revealed that FOXO1
and MYC were more highly expressed in HCT116 cells (Fig. 5d,
e). On the other hand, TFs including STAT1 and FOS received
higher IF in EGFRNetmtKRAS-Lo, and their gene expression was
signiﬁcantly elevated in HKE3 cells (Fig. 5f, g). These results were
consistent with the IF model predictions. Next, we analyzed TF
binding sites in the promoters of genes that were differentially
regulated between mtKRASHi and mtKRASLo cells. Genes
upregulated in mtKRASHi cells were enriched for MYC binding
sites (Fig. 5h), consistent with the prediction that MYC receives
more IF through EGFRNetmtKRAS-Hi. Conversely, genes upregu-
lated in mtKRASLo were enriched for the interferon-stimulated
response element (ISRE) motif (Fig. 5i), a key motif in the
promoters of STAT1/2-regulated genes48. The difference in FOS
gene expression between the cell lines was particularly evident 60
min post-TGFα stimulation. Consistent with the prediction of
higher FOS regulation through EGFRNetmtKRAS-Lo, the AP-1
binding site motif for FOS/JUN dimers was enriched in the
promoters of genes upregulated in mtKRASLo cells at this
timepoint (data not shown). The prediction that STAT1 receives
lower IF in EGFRNetmtKRAS-Hi is consistent with reports that
mtKRAS inhibits STAT1/2 expression49. To directly examine
STAT activity, we used luciferase reporter genes that are regulated
by STAT1/2/3 TFBS (Fig. 5j). STAT1/2 reporter activity was
signiﬁcantly elevated in mtKRASLo, while STAT3 activity was
similar in mtKRASHi and mtKRASLo cells.
In summary, these data suggest that mtKRAS mediated PPIN
rewiring alters signal ﬂow through the EGFR network leading to
the induction of different transcriptional programs. These
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analyses also support our PPIN reconstruction and the functional
consequences of PPIN rewiring by unbiased global approaches.
Alterations in rewired baits predict CRC patient survival. The
results presented above suggest that PPIN rewiring is associated
with mtKRAS signaling and oncogenic potential. Therefore, we
investigated whether alterations in bait proteins showing the most
rewiring were prognostic of CRC patients’ clinical outcomes. We
assessed survival data of 629 CRC patients from the TCGA
dataset50. Fifty-four percent of patients had genetic or expression
alterations in the top 20 most rewired bait proteins, as deﬁned by
the sum of rewired interactions associated with each bait (Fig. 6a,
Supplementary Data 15). Patients with alterations in top 20 most
rewired baits had signiﬁcantly poorer survival (P < 0.04) than
patients without alterations in these proteins (Fig. 6b). Ten-year
survival was 34.61% for patients with alterations in the top 20
rewired baits vs. 61.43% for patients without. These data were
robust to removing the bottom 50% of least signiﬁcant (based on
the signiﬁcance A value) rewired interactions from the rewiring
analysis and recalculating the top 20 most rewired baits. 18 of the
20 original top 20 baits were the same in this analysis (data not
shown). By contrast, there was no signiﬁcant association between
alterations in the 20 least rewired bait proteins (Fig. 6c) and
patient survival (P= 0.20) (Fig. 6d), although all of these baits
were preselected because of their roles in the EGFR pathway. This
association with survival became even stronger (P= 9.855e−3), if
we deﬁned the top 20 most rewired baits based on interactions
that were selectively enhanced in the mtKRASHi cells (Supple-
mentary Fig. 9A).
To assess the accuracy of the top-20 bait proteins to classify
patients into high and low risk groups, we trained a Lasso
classiﬁer51 using the CRC patient data from TCGA. Five-fold
cross-validation by subsampling the patient data into training
(80%) and test (20%) datasets gave an accuracy of up to 0.79
(mean 0.70) and an area under the ROC curve (AUC) of 0.763
(Supplementary Fig. 9B). A similar classiﬁcation using the bottom
20 least rewired proteins gave a much lower mean accuracy of 0.4
and AUC of 0.522. Several top rewired baits were highly
connected nodes. Therefore, to ascertain that the association
with patient outcomes was due to the rewiring of these baits and
not just because they were highly connected, we selected the
bottom 36 least rewired baits that together accounted for at least
the same number of interactions as the top 20 baits. Patients with
alterations in the top 20 rewired baits again showed signiﬁcantly
poorer survival (P < 0.017, log-rank test) than patients with
alterations in these baits. (Supplementary Fig. 9C). Patients with
alterations in the top 20 rewired baits also showed signiﬁcantly
poorer survival after adjusting for age and tumor stage (P < 0.03,
log-rank test). These data suggest that the proteins, which we
found to be the most rewired in mtKRASHi cells, are clinically
relevant as alterations in these proteins are prognostic of CRC
patient outcomes.
Discussion
Global PPIN mapping has validated the concept that the cell
organizes its proteome as modules of PPIs that enable it to carry
out its speciﬁc biological functions1,2,4. Many disease-associated
mutations affect PPIs25, but the extent of adaption to disease
mutations at a PPIN level and its functional consequences are
unknown. Our comparative mapping of >6000 PPIs in the EGFR
network in cells with low and high mtKRAS signaling reveals a
widespread rewiring of the EGFR signaling network. Interest-
ingly, rewiring percolates through the whole network and alters
interactions that occur between core components of the EGFR
pathway as well as interactions between proteins involved in
downstream and seemingly peripheral processes. This suggests
that enhanced mtKRAS activity results in extensive adaptive
changes that are reﬂected by a reorganization of the PPIN.
Genetic mutations associated with disease often alter PPIs25.
However, the deep network propagation of PPI changes arising
from a single mutation was unexpected and may explain why
blocking mtKRAS signaling by inhibiting single effector pathways
is ineffective8. Our global analysis and validation of the functional
consequences of PPIN rewiring facilitates the rational design of
combinatorial targeting of mtKRAS effectors, especially as PPIs
gained in mtKRASHi cells inversely correlate with CRC patient
survival. For instance, HSPs receive high IF in mtKRASHi cells,
and HSP90 inhibitors recently were found to enhance the effects
of conventional CRC drug therapies52. Likewise, our results that
phosphorylation changes contribute to PPIN rewiring may
“repurpose” kinase inhibitors as PPIN rewiring agents. We
recently showed that mtKRAS also profoundly changes the
metabolic and transcriptional landscapes of CRC cells53 con-
ﬁrming that mtKRAS widely affects cellular regulation on dif-
ferent levels. Surprisingly, our analysis shows that a low-level
expression of mtKRAS is compatible with normal (i.e., untrans-
formed) biochemical and biological behavior. This ﬁnding sug-
gests that oncogenic mutations must reach a threshold activity
before they produce a pathogenetic phenotype. While this view
challenges the genetic mutational dogma of carcinogenesis, it
reconciles with recent data ﬁnding oncogenic mutations in nor-
mal tissues54,55. The easy accessibility and analysis of our PPIN
data through PRIMESDB.eu and DyNet56, an application for the
visualization and analysis of dynamic molecular interaction net-
works will support systematic efforts of combinatorial mtKRAS
pathway targeting.
While our study is comprehensive and integrates PPIN
reconstruction with computational model analysis of network
functions, it also has limitations. Although we have thoroughly
characterized the two cell lines by WGS, biochemical and bio-
logical assays, we cannot formally exclude that differences other
than mtKRAS activities contribute to our results, e.g., differ-
ential bait expression vs. endogenous levels, epigenetic differ-
ences, or nonsynonymous mutations that affect splicing or
codon usage. The inﬂuence of such factors could be addressed
by reconstitution experiments that titrate mtKRAS dosage and
by studying other isogenic cell line pairs. Investigating all these
aspects was beyond the scope of this study. However, we
assessed and found no statistical association between rewiring
and alternative splicing (data not shown), which in binary
interaction screens substantially changed PPIs57. It also will be
important to test whether the observed PPI rewiring is common
to different mtKRAS cancer types. Our ﬁndings that PPI
changes correlate with CRC patient prognosis and often affect
proteins that are synthetic lethal with KRASG13D33 indicate that
a core signature of consistently altered PPIs may exist in
mtKRAS cells.
In summary, these results suggest that dynamic PPIN adap-
tations play major roles in translating the effects of genetic
mutations into quantitative functional effects that re-direct
information ﬂow through signaling networks and reprogram
biological outcomes.
Methods
Cell lines and cell culture. HCT116 (mtKRASHi) and HKE3 (mtKRASLo) cells11
were provided by Drs Shirasawa and Sasazuki. Cell lines were authenticated by
whole genome sequencing (Supplementary Datas 6–8) and RNAseq as recently
described12.
Baits and expression vectors. For AP-MS experiments 95 baits (Supplementary
Data 1) were selected that provide a broad coverage of the known EGFR signaling
network. Bait cDNAs were obtained from Origene and cloned into the SF-TAP
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vector58 with the FLAG-tag at the N-terminus using the Gateway cloning system
(Thermo Fisher).
AP-MS experiments. Cells were transfected with baits titrated to achieve similar
expression levels between the cell lines and labeled with stable isotope (SILAC)
medium (Fig. 1). Baits were immunoprecipitated with anti-FLAG-M2 conjugated
agarose beads (Sigma-Aldrich A2220), digested with trypsin and analyzed by
quantitative MS using a Q-Exactive mass spectrometer (Thermo Fisher Scientiﬁc).
Data were analyzed with MaxQuant59 and HiQuant19 software packages. See
Supplementary Methods, sections 8–12, for a detailed description.
Protein expression proﬁling. Lysates of SILAC labeled cells were digested with
trypsin and analyzed on an Orbitrap Fusion Tribrid mass spectrometer (Thermo
Fisher Scientiﬁc). Data were analyzed with MaxQuant59 and HiQuant19 software
packages. See Supplementary Methods, sections 13–15, for a detailed description.
Phosphoproteomics. Cell lysates were digested with trypsin, phosphopeptides
were enriched using TiO2 beads and analyzed on a Q-Exactive mass spectrometer
(Thermo Fisher Scientiﬁc). MS data were analyzed with MASCOT 2.4 (Matrix
Science Ltd) and Progenesis 4 (Nonlinear Dynamics). See Supplementary Methods,
sections 16–18, for a detailed description.
Construction of protein–protein interaction networks (PPIN). The EGFR-
NetmtKRAS-Hi and EGFRNetmtKRAS-Lo networks were separately constructed by
combining bait–prey interactions from each of the 95 chosen baits. Bait-prey
interactions were included in the networks, if the abundance of the prey protein in
the pull-down was signiﬁcantly higher (P ≤ 0.05) than in empty vector controls and
the signiﬁcance A value for the prey protein was also ≤0.05. To identify interactions
that were signiﬁcantly “rewired” in the HCT116 (EGFRNetmtKRAS-Hi) network
compared to the HKE3 (EGFRNetmtKRAS-Lo) network, we used HiQuant to directly
compare the SILAC data from the two cell lines. We deﬁned interactions as being
“rewired” in EGFRNetmtKRAS-Hi, if the abundance of the prey protein in the pull-
down was signiﬁcantly different (P ≤ 0.05) compared to EGFRNetmtKRAS-Lo and
the signiﬁcance A value for the prey protein was also ≤0.05. Interactions that were
identiﬁed in only one EGFRNet, but where prey abundance was subsequently not
found to be statistically signiﬁcantly different in the respective bait–prey complexes
in the two cell lines were not considered as rewired interactions. The top rewired
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Fig. 6 PPIN rewiring and CRC prognosis. a The top 20 most rewired bait proteins. Interactions where the prey protein was identiﬁed only in
EGFRNetmtKRAS-Hi or EGFRNetmtKRAS-Lo are shown as solid red or blue lines, respectively. Rewired bait-prey interactions where prey abundance was
signiﬁcantly higher in EGFRNetmtKRAS-Hi or EGFRNetmtKRAS-Lo are shown as dotted red or blue lines, respectively. Bait–prey interactions which were not
signiﬁcantly different are gray. b Six hundred and twenty-nine CRC patients from the TCGA were divided into two groups, those with alterations in the top
20 rewired bait proteins (339; 54%) and those without alterations in the top 20 rewired bait proteins (290; 46%). The alterations assessed were
mutations, copy number changes, mRNA expression changes, and protein expression changes. Kaplan–Meier survival curves were plotted for the two
patient groups using PRISM 7.0.3. Five-year survival was 53.5% for patients with genetic alterations affecting the top 20 rewired nodes compared to 68.5%
for patients without alterations in these proteins, and ten-year survival was 34.61 vs. 61.43%, respectively. The log-rank test was used to assess statistical
signiﬁcance. c The bottom 20 least rewired bait proteins. d There was no signiﬁcant (NS) difference in survival between patients with alterations in the
bottom 20 least rewired bait proteins and those without. Source data are provided as a Source Data ﬁle.
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nodes in EGFRNetmtKRAS-Hi were identiﬁed as those with most rewired interac-
tions. The topological properties of the networks including node degree,
betweenness centrality, clustering coefﬁcient and network scale-freeness were
analyzed using the NetworkAnalyzer application60 in Cytoscape 361. Cytoscape
session ﬁles for the EGFRNetmtKRAS-Hi, EGFRNetmtKRAS-Lo networks can be
provided upon request.
Protein abundance and phosphorylation enrichment analysis. To investigate
whether nodes in the EGFRNetmtKRAS-Hi network were enriched for differentially
abundant proteins, a hypergeometric test was performed with the following
parameters:
p X  kð Þ ¼
Xn
x¼ k
K
x
 
N  K
n x
 
N
n
  ;
where N is the total number of proteins assayed in the protein expression analysis,
n the total number of differentially abundant proteins identiﬁed, K the number of
proteins in the EGFRNetmtKRAS-Hi network that were assayed in the protein
expression analysis, k the number of differentially abundant proteins observed in
the EGFRNetmtKRAS-Hi network.
A similar analysis was conducted to determine whether rewired nodes were
enriched for differentially abundant or phosphorylated proteins. See
Supplementary Methods, section 19, for a detailed description.
Equilibrium binding model of RAS binding partners to RAS-GTP. In order to
determine how the concentrations of KRAS-effector complexes change with the
concentration of active RAS in mtKRASHi and mtKRASLo cells, we developed a
dynamic mathematical model that allowed us to investigate how competition for
the single effector binding site on RAS and different abundances of low and high
afﬁnity RAS effectors impact the formation of RAS-effector complexes. See Sup-
plementary Methods, sections 22–25, for a detailed description.
Information ﬂow analysis of EGFRNetmtKRAS-Hi and EGFRNetmtKRAS-Lo net-
works. In order to analyze how the EGFR PPINs transduce information we
employed a computational modeling approach called information ﬂow (IF) ana-
lysis62,63. To perform IF analysis from the EGFR at the cell membrane to nuclear
transcription factors (TFs), the two EGFRNets were ﬁrst supplemented with
publicly available prey–prey interactions from InnateDB.com64 and 122 additional
nodes that are known to be involved in EGFR signaling18 but were not chosen as
bait proteins in our AP-MS experiments (Supplementary Data 14). These networks
are referred to as the HCT116IFANET and HKE3IFANET. Information ﬂow analysis
was implemented using the CytoITMprobe software (damping factor= 0.85;
channel model selected)41, selecting EGFR as the source node of signaling and 19
downstream TFs (Supplementary Data 14) as the sinks for the information ﬂow.
Information ﬂow scores were determined by measuring how much information
ﬂows through each node in the HCT116IFANET and HKE3IFANET networks. See
Supplementary Methods, section 26, for a detailed description.
Gene ontology, pathway, and transcription factor binding site analyses. Gene
ontology (GO) and pathway analyses were performed using InnateDB.com64
regarding GO terms or pathways with an FDR < 0.05 as signiﬁcantly enriched.
Transcription factor binding site analysis was undertaken using the ﬁndMotifs.pl
program in HOMER v4.865, with the human hg38 promoter set in order to identify
enriched motifs. See Supplementary Methods, section 27, for a detailed description.
Analysis of CRC patient data. Survival data of 629 CRC patients were obtained
from the TCGA50, and correlated with alterations in genes encoding either the top
20 most rewired or the bottom 20 least rewired bait proteins. The alterations
included were mutations, copy number changes, mRNA expression changes, and
protein expression changes. As an additional control we selected a set of 36 baits
that accounted for the same number of interactions as the top 20 baits in the
network. The Kaplan–Meier curves were plotted using PRISM 7.0.3. See Supple-
mentary Methods, section 27, for a detailed description.
Western blotting. Cells were lysed in 1% NP40, 20 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 mM MgCl2) supplemented with protease inhibitor cocktail (Roche) and
phosphatase inhibitors (2 mM sodium orthovanadate, 10 mM sodium ﬂuoride and
10 mM β-glycerophosphate; all from Sigma-Aldrich) for 10 min at 4 °C. Lysates
were cleared by centrifugation at 20,000 × g for 10 min, and adjusted to equal
protein concentrations. Proteins were separated by sodium-dodecylsulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene
diﬂuoride (PVDF) membranes. Blots were incubated with the respective antibodies
and developed using Enhanced Chemiluminescence (ECL; Thermo Fisher)
according to the manufacturer’s instructions. Blots were quantiﬁed using the Image
J software and phospho-speciﬁc antibody signals were normalized to the total
abundance of the respective proteins.
Luciferase assays. The transcription factor response element activity was assessed
with luciferase constructs bearing response elements for STAT1 (4xGAS response
element; Stratagene, #219091–51), STAT1/STAT2 (IRSE/interferon alpha response
element66) and STAT3 (4xm67 response element67). A CMV-β-gal plasmid was co-
transfected as a control of transfection efﬁciency. Forty-eight hours post transfection
cells were stimulated with 10 nm human EGF (Roche; #11376454001) for 5 h before
luciferase and β-gal activity were measured using luciferase assay (Promega, #E4030)
and β-galactosidase assay kits (Promega, #E2000). Luciferase activity was normalized
againstβ-gal activity to correct for transfection efﬁciency.
Transcriptional proﬁling. HCT116 (mtKRASHi) and HKE3 (mtKRASLo) cells
were serum starved for 18 h before stimulation with TGF-α (0.01 µg/ml, Abcam)
for 0, 15, 30, 60, 90, and 120 min. RNA was extracted using the TRIzol reagent
(Thermo Fisher Scientiﬁc) from three biological replicates at each time point.
RNAseq was performed with an Illumina HiSeq 2500 machine using a v2 High
Output 100 cycle Kit (1 × 100 bp SR). Data were processed as described in the
Supplementary Methods.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
RNAseq data were deposited in the Gene Expression Omnibus under accession number
GSE105094. These data were used in Fig. 5d-i and Supplementary Fig. 5B. Whole
genome sequencing data were deposited in the NCBI short read archive under accession
number PRJNA374513. They were used in Supplementary Fig. 5A. Proteomics data were
deposited in the PRIDE database under the following accession numbers: PXD016512,
PXD016505, PXD016465, PXD016464, PXD016463, PXD016462, PXD016461 for the
AP-MS data, PXD016549 for the protein expression proﬁling data, and PXD016431 for
the phosphoproteomics data. AP-MS data can be visualized and browsed in PRIMESDB,
a database developed for this project and described in detail in the Supplementary Data.
PRIMESDB is accessible at primesdb.eu. is an observer member of The International
Molecular Exchange (IMEx) consortium, the international standards body for the
curation and exchange of published protein-protein interaction data68. These data were
used in Figs. 2, 3, 5b, 6 and Supplementary Figs. 2, 4, 6, 7, 9. All PPI data generated in this
study also been deposited with IMEx (IMEx accession number IM-26434). TCGA data
were obtained from https://www.cbioportal.org/study/summary?id=coadread_tcga. The
source data underlying Figs. 2a–c, 3a–c, 4a–d, 5a–j, 6a–d and Supplementary Figs. 1b–i,
2a-i, 3a–c, 4, 5a–f, 6a, b, 7, 8b–e, 9a–c are provided as a Source Data ﬁle
Code availability
Mathematica, R, and Cytoscape ﬁles with code are provided as Supplementary Software:
Supplementary Software 1. Mathematica code for Fig. 5a. Supplementary Software 2.
Cytoscape session ﬁle for Supplementary Fig. 2A. Supplementary Software 3. R-code and
source data used for Supplementary Fig. 3A. Supplementary Software 4. Cytoscape session
ﬁle for Supplementary Fig. 5C, D. Supplementary Software 5. Cytoscape session ﬁle for
Supplementary Fig. 5E, F. Supplementary Software 6. Cytoscape session ﬁle for
Supplementary Fig. 6A, B. Supplementary Software 7. R-script for Supplementary Fig. 9B.
Received: 11 May 2019; Accepted: 5 December 2019;
References
1. Hein, M. Y. et al. A human interactome in three quantitative dimensions
organized by stoichiometries and abundances. Cell 163, 712–723 (2015).
2. Rolland, T. et al. A proteome-scale map of the human interactome network.
Cell 159, 1212–1226 (2014).
3. Vidal, M., Cusick, M. E. & Barabasi, A. L. Interactome networks and human
disease. Cell 144, 986–998 (2011).
4. Huttlin, E. L. et al. Architecture of the human interactome deﬁnes protein
communities and disease networks. Nature 545, 505–509 (2017).
5. Ryan, C. J. et al. High-resolution network biology: connecting sequence with
function. Nat. Rev. Genet. 14, 865–879 (2013).
6. Taylor, I. W. & Wrana, J. L. Protein interaction networks in medicine and
disease. Proteomics 12, 1706–1716 (2012).
7. Hobbs, G. A., Der, C. J. & Rossman, K. L. RAS isoforms and mutations in
cancer at a glance. J. Cell Sci. 129, 1287–1292 (2016).
8. Papke, B. & Der, C. J. Drugging RAS: know the enemy. Science 355,
1158–1163 (2017).
9. Er, T. K., Chen, C. C., Bujanda, L. & Herreros-Villanueva, M. Clinical relevance
of KRAS mutations in codon 13: Where are we? Cancer Lett. 343, 1–5 (2014).
10. Markman, B., Javier Ramos, F., Capdevila, J. & Tabernero, J. EGFR and KRAS
in colorectal cancer. Adv. Clin. Chem. 51, 71–119 (2010).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14224-9
12 NATURE COMMUNICATIONS |          (2020) 11:499 | https://doi.org/10.1038/s41467-019-14224-9 | www.nature.com/naturecommunications
11. Shirasawa, S., Furuse, M., Yokoyama, N. & Sasazuki, T. Altered growth of human
colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85–88 (1993).
12. Fasterius, E. et al. A novel RNA sequencing data analysis method for cell line
authentication. PLoS ONE 12, e0171435 (2017).
13. Boutin, A. T. et al. Oncogenic Kras drives invasion and maintains metastases
in colorectal cancer. Genes Dev. 31, 370–382 (2017).
14. Mueller, S. et al. Evolutionary routes and KRAS dosage deﬁne pancreatic
cancer phenotypes. Nature 554, 62–68 (2018).
15. Anglesio, M. S. et al. Cancer-associated mutations in endometriosis without
cancer. N. Engl. J. Med. 376, 1835–1848 (2017).
16. Parsons, B. L., McKim, K. L. & Myers, M. B. Variation in organ-speciﬁc
PIK3CA and KRAS mutant levels in normal human tissues correlates with
mutation prevalence in corresponding carcinomas. Environ. Mol. Mutagen.
58, 466–476 (2017).
17. Matallanas, D. et al. Mutant K-Ras activation of the proapoptotic MST2
pathway is antagonized by wild-type K-Ras. Mol. Cell 44, 893–906 (2011).
18. Kiel, C., Verschueren, E., Yang, J. S. & Serrano, L. Integration of protein
abundance and structure data reveals competition in the ErbB signaling
network. Sci. Signal. 6, ra109 (2013).
19. Bryan, K. et al. HiQuant: rapid postquantiﬁcation analysis of large-scale MS-
generated proteomics data. J. Proteome Res. 15, 2072–2079 (2016).
20. Bisson, N. et al. Selected reaction monitoring mass spectrometry reveals the
dynamics of signaling through the GRB2 adaptor. Nat. Biotechnol. 29,
653–658 (2011).
21. Kotlyar, M., Pastrello, C., Sheahan, N. & Jurisica, I. Integrated interactions
database: tissue-speciﬁc view of the human and model organism interactomes.
Nucleic Acids Res. 44, D536–D541 (2016).
22. Kotlyar, M., Pastrello, C., Malik, Z. & Jurisica, I. IID 2018 update: context-
speciﬁc physical protein–protein interactions in human, model organisms and
domesticated species. Nucleic Acids Res. 47, D581–d589 (2019).
23. Lu, B., McClatchy, D. B., Kim, J. Y. & Yates, J. R. III Strategies for shotgun
identiﬁcation of integral membrane proteins by tandem mass spectrometry.
Proteomics 8, 3947–3955 (2008).
24. Sokolina, K. et al. Systematic protein–protein interaction mapping for
clinically relevant human GPCRs. Mol. Syst. Biol. 13, 918 (2017).
25. Sahni, N. et al. Widespread macromolecular interaction perturbations in
human genetic disorders. Cell 161, 647–660 (2015).
26. Van der Auwera, G. A. et al. From FastQ data to high conﬁdence variant calls:
the Genome Analysis Toolkit best practices pipeline. Curr. Protoc. Bioinform.
43, 11.10.11–33 (2013).
27. McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122
(2016).
28. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science 324,
1029–1033 (2009).
29. Kerr, E. M., Gaude, E., Turrell, F. K., Frezza, C. & Martins, C. P. Mutant Kras
copy number deﬁnes metabolic reprogramming and therapeutic
susceptibilities. Nature 531, 110–113 (2016).
30. Beloribi-Djefaﬂia, S., Vasseur, S. & Guillaumond, F. Lipid metabolic
reprogramming in cancer cells. Oncogenesis 5, e189 (2016).
31. McShane, E. et al. Kinetic analysis of protein stability reveals age-dependent
degradation. Cell 167, 803–815 (2016).
32. Wang, J. et al. Proteome proﬁling outperforms transcriptome proﬁling for
coexpression based gene function prediction. Mol. Cell Proteom. 16, 121–134
(2017).
33. Martin, T. D. et al. A role for mitochondrial translation in promotion of
viability in K-Ras mutant cells. Cell Rep. 20, 427–438 (2017).
34. Ruepp, A. et al. CORUM: the comprehensive resource of mammalian protein
complexes-2009. Nucleic Acids Res. 38, D497–D501 (2010).
35. Shostak, K. & Chariot, A. EGFR and NF-kappaB: partners in cancer. Trends
Mol. Med. 21, 385–393 (2015).
36. Avraham, R. & Yarden, Y. Feedback regulation of EGFR signalling: decision
making by early and delayed loops. Nat. Rev. Mol. Cell Biol. 12, 104–117 (2011).
37. Danial, N. N. BAD: undertaker by night, candyman by day. Oncogene 27
(Suppl 1), S53–S70 (2008).
38. Ahn, J. H. et al. Protein kinase A activates protein phosphatase 2A by
phosphorylation of the B56delta subunit. Proc. Natl Acad. Sci. USA 104,
2979–2984 (2007).
39. Mathur, P. S. et al. Kinase-dependent and -independent roles for PTK6 in
colon cancer. Mol. Cancer Res. 14, 563–573 (2016).
40. Covington, K. R. & Fuqua, S. A. Role of MTA2 in human cancer. Cancer
Metastasis Rev. 33, 921–928 (2014).
41. Stojmirovic, A., Bliskovsky, A. & Yu, Y. K. CytoITMprobe: a network
information ﬂow plugin for Cytoscape. BMC Res. Notes 5, 237 (2012).
42. Stojmirovic, A. & Yu, Y. K. ITM Probe: analyzing information ﬂow in protein
networks. Bioinformatics 25, 2447–2449 (2009).
43. Belov, A. A. & Mohammadi, M. Grb2, a double-edged sword of receptor
tyrosine kinase signaling. Sci. Signal. 5, pe49 (2012).
44. Milicevic, Z. T., Petkovic, M. Z., Drndarevic, N. C., Pavlovic, M. D. &
Todorovic, V. N. Expression of heat shock protein 70 (HSP70) in patients with
colorectal adenocarcinoma-immunohistochemistry and Western blot analysis.
Neoplasma 54, 37–45 (2007).
45. Bauer, K. et al. High HSP27 and HSP70 expression levels are independent
adverse prognostic factors in primary resected colon cancer. Cell Oncol. 35,
197–205 (2012).
46. Chatterjee, S. & Burns, T. F. Targeting heat shock proteins in cancer: a
promising therapeutic approach. Int. J. Mol. Sci. 18, 1978 (2017).
47. Chen, J., Elﬁky, A., Han, M., Chen, C. & Saif, M. W. The role of Src in colon
cancer and its therapeutic implications. Clin. Colorectal Cancer 13, 5–13 (2014).
48. Shaulian, E. AP-1-The Jun proteins: oncogenes or tumor suppressors in
disguise? Cell Signal 22, 894–899 (2010).
49. Klampfer, L. et al. Oncogenic Ki-ras inhibits the expression of interferon-
responsive genes through inhibition of STAT1 and STAT2 expression. J. Biol.
Chem. 278, 46278–46287 (2003).
50. Zhang, B. et al. Comprehensive molecular characterization of human colon
and rectal cancer. Nature 487, 330–337 (2012).
51. Tibshirani, R. Regression shrinkage and selection via the Lasso. J. R. Stat. Soc.
58, 267–288 (1996).
52. Kryeziu, K., Bruun, J., Guren, T. K., Sveen, A. & Lothe, R. A. Combination
therapies with HSP90 inhibitors against colorectal cancer. Biochim. et.
Biophys. Acta 1871, 240–247 (2019).
53. Charitou, T. et al. Transcriptional and metabolic rewiring of colorectal cancer
cells expressing the oncogenic KRAS(G13D) mutation. Br. J. Cancer 121,
37–50 (2019).
54. Francis, J. H. et al. BRAF, NRAS, and GNAQ mutations in conjunctival
melanocytic nevi. Investig. Ophthalmol. Vis. Sci. 59, 117–121 (2018).
55. Martincorena, I. et al. Tumor evolution. High burden and pervasive positive
selection of somatic mutations in normal human skin. Science 348, 880–886
(2015).
56. Goenawan, I. H., Bryan, K. & Lynn, D. J. DyNet: visualization and analysis of
dynamic molecular interaction networks. Bioinformatics 32, 2713–2715 (2016).
57. Yang, X. et al. Widespread expansion of protein interaction capabilities by
alternative splicing. Cell 164, 805–817 (2016).
58. Gloeckner, C. J., Boldt, K., Schumacher, A., Roepman, R. & Uefﬁng, M. A
novel tandem afﬁnity puriﬁcation strategy for the efﬁcient isolation and
characterisation of native protein complexes. Proteomics 7, 4228–4234 (2007).
59. Cox, J. & Mann, M. MaxQuant enables high peptide identiﬁcation rates,
individualized p.p.b.-range mass accuracies and proteome-wide protein
quantiﬁcation. Nat. Biotechnol. 26, 1367–1372 (2008).
60. Doncheva, N. T., Assenov, Y., Domingues, F. S. & Albrecht, M. Topological
analysis and interactive visualization of biological networks and protein
structures. Nat. Protoc. 7, 670–685 (2012).
61. Shannon, P. et al. Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res. 13, 2498–2504 (2003).
62. Stojmirovic, A. & Yu, Y. K. Information ﬂow in interaction networks. J.
Comput Biol. 14, 1115–1143 (2007).
63. Stojmirovic, A. & Yu, Y. K. Information ﬂow in interaction networks II:
channels, path lengths, and potentials. J. Comput Biol. 19, 379–403 (2012).
64. Breuer, K. et al. InnateDB: systems biology of innate immunity and beyond-
recent updates and continuing curation. Nucleic Acids Res. 41, D1228–D1233
(2013).
65. Heinz, S. et al. Simple combinations of lineage-determining transcription
factors prime cis-regulatory elements required for macrophage and B cell
identities. Mol. Cell 38, 576–589 (2010).
66. John, S., Vinkemeier, U., Soldaini, E., Darnell, J. E. Jr & Leonard, W. J. The
signiﬁcance of tetramerization in promoter recruitment by Stat5. Mol. Cell
Biol. 19, 1910–1918 (1999).
67. Horvath, C. M., Wen, Z. & Darnell, J. E. Jr A STAT protein domain that
determines DNA sequence recognition suggests a novel DNA-binding
domain. Genes Dev. 9, 984–994 (1995).
68. Orchard, S. et al. Protein interaction data curation: the International
Molecular Exchange (IMEx) consortium. Nat. Methods 9, 345–350 (2012).
Acknowledgements
This work was supported by European Union FP7 Grant No. 278568 “PRIMES” and
Science Foundation Ireland Investigator Program Grant 14/IA/2395 to W.K. B.K. is
supported by SmartNanoTox (Grant no. 686098), NanoCommons (Grant no. 731032),
O.R. by MSCA-IF-2016 SAMNets (Grant no. 750688). D.M. is supported by Science
Foundation Ireland Career Development award 15-CDA-3495. I.J. is supported by the
Canada Research Chair Program (CRC #225404), Krembil Foundation, Ontario Research
Fund (GL2-01-030 and #34876), Natural Sciences Research Council (NSERC #203475),
Canada Foundation for Innovation (CFI #225404, #30865), and IBM. D.J.L. is supported
by EMBL Australia. O.S. is supported by ERC investigator Award ColonCan 311301 and
CRUK. I.S. is supported by the Canadian Cancer Society Research Institute (#703889),
Genome Canada via Ontario Genomics (#9427 & #9428), Ontario Research fund (ORF/
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14224-9 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:499 | https://doi.org/10.1038/s41467-019-14224-9 | www.nature.com/naturecommunications 13
DIG-501411 & RE08-009), Consortium Québécois sur la Découverte du Médicament
(CQDM Quantum Leap) & Brain Canada (Quantum Leap), and CQDM Explore and
OCE (#23929). T.C. was supported by a Teagasc Walsh Fellowship. MU and KB are
supported by the Tistou & Charlotte Kerstan Stiftung. We thank Prof M. Uhlen for
discussions and critical review of the HKE3 and HCT116 genome analysis. PRIMESDB
(primesdb.eu) is supported by use of the NeCTAR Research Cloud and by eResearch SA.
The NeCTAR Research Cloud is a collaborative Australian research platform supported
by the National Collaborative Research Infrastructure Strategy.
Author contributions
The study was designed by W.K., D.J.L., and K.Bo. with input from M.U., L.S., C.K., and
I.S. M.A.J., S.K., C.R., N.H., F.K., T.L., L.I., K.Bo., and V.W. performed proteomics
experiments. S.K., C.H.M., A.K., D.M., M.A.J., L.D., N.R., C.K., R.P., P.C., and O.S.
performed biochemical and biological experiments. E.F. and C.A.S. did the whole gen-
ome sequencing and some of the RNAseq experiments. D.J.L., S.Sr., M.A.J., K.Br., S.Sh.,
K.Bo., J.B., and M.A. analyzed the data. T.C. performed the information ﬂow analysis and
corresponding experiments including RNAseq with M.A.L., A.K., and D.J.L. PRIMESDB
was developed by M.B.L., K.Br., P.P., and D.J.L. I.J., M.K., J.C., and I.S. contributed the
MYTH experiments. B.N.K. and O.R. generated the mathematical model. LFIM and C.R.
performed the dynamic complex analysis. D.J.L., S.Sr., and W.K. wrote the paper with
contributions from all other authors.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
019-14224-9.
Correspondence and requests for materials should be addressed to K.B., D.J.L. or W.K.
Peer review information Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
Susan A. Kennedy1,27, Mohamed-Ali Jarboui 2,3,27, Sriganesh Srihari4,5,27, Cinzia Raso1,27, Kenneth Bryan4,
Layal Dernayka2, Theodosia Charitou1,4, Manuel Bernal-Llinares 4, Carlos Herrera-Montavez1,
Aleksandar Krstic1, David Matallanas 1, Max Kotlyar6, Igor Jurisica6,7,8, Jasna Curak9,10,11, Victoria Wong9,10,11,
Igor Stagljar 9,10,11,12, Thierry LeBihan13, Lisa Imrie 13, Priyanka Pillai4, Miriam A. Lynn4, Erik Fasterius 14,
Cristina Al-Khalili Szigyarto 14,15, James Breen16,17, Christina Kiel1,18,19, Luis Serrano 18, Nora Rauch 1,
Oleksii Rukhlenko1, Boris N. Kholodenko1,19,20, Luis F. Iglesias-Martinez1, Colm J. Ryan 1,21, Ruth Pilkington1,
Patrizia Cammareri22, Owen Sansom 22,23, Steven Shave 24, Manfred Auer 24, Nicola Horn2,
Franziska Klose2, Marius Uefﬁng2, Karsten Boldt 2,28*, David J. Lynn4,25,28* & Walter Kolch 1,19,26,28*
1Systems Biology Ireland, University College Dublin, Dublin, Ireland. 2Institute for Ophthalmic Research, University of Tübingen, Tübingen, Germany.
3Werner Siemens Imaging Center, University of Tübingen, Tübingen, Germany. 4EMBL Australia Group, South Australian Health and Medical
Research Institute, Adelaide, SA 5000, Australia. 5QIMR-Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. 6Krembil Research
Institute, University Health Network, Toronto, Canada. 7Departments of Medical Biophysics and Computer Science, University of Toronto,
Toronto, Canada. 8Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic. 9Donnelly Centre, University of Toronto,
Toronto, Canada. 10Department of Biochemistry, University of Toronto, Toronto, Canada. 11Department of Molecular Genetics, University of
Toronto, Toronto, Canada. 12Mediterranean Institute for Life Sciences, Split, Croatia. 13Synthetic and Systems Biology, University of Edinburgh,
Edinburgh, UK. 14School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden. 15Science for Life Laboratory, KTH Royal Institute
of Technology, Stockholm, Sweden. 16School of Biological Sciences, University of Adelaide Bioinformatics Hub, Adelaide, SA, Australia.
17Computational & Systems Biology Program, South Australian Health and Medical Research Institute, Adelaide, SA, Australia. 18Centre for
Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain. 19Conway Institute, University College Dublin, Dublin, Ireland.
20Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA. 21School of Computer Science, University College
Dublin, Dublin, Ireland. 22Cancer Research UK Beatson Institute, Glasgow, UK. 23Institute of Cancer Studies, Glasgow University, Glasgow, UK.
24School of Biological Sciences and School of Biomedical Sciences, University of Edinburgh, Edinburgh, UK. 25College of Medicine and Public Health,
Flinders University, Bedford Park, SA 5042, Australia. 26School of Medicine, University College Dublin, Dublin, Ireland. 27These authors contributed
equally: Susan A. Kennedy, Mohamed-Ali Jarboui, Sriganesh Srihari, Cinzia Raso. 28These authors jointly supervised: Karsten Boldt, David J. Lynn,
Walter Kolch. *email: karsten.boldt@uni-tuebingen.de; david.lynn@sahmri.com; walter.kolch@ucd.ie
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14224-9
14 NATURE COMMUNICATIONS |          (2020) 11:499 | https://doi.org/10.1038/s41467-019-14224-9 | www.nature.com/naturecommunications
